Loading…
MTNB
Matinas BioPharma Holdings, Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 576810303
$0.200.00%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $2.94M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.15
- ROE
- -141.24%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.75
- 52-week high
- $2.14
- 52-week low
- $0.18
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.7% over 5Y.
today you would have $2.46▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.59 | $0.51 | $10.80 | $25.00 | |
| P/S | — | — | — | 42.8x | 34.1x |
| P/B | 1.6x | 0.8x | 0.3x | 2.4x | 3.0x |
| EPS | -$2.00 | -$4.98 | -$5.28 | -$5.00 | |
| Profit margin | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MEDSDataMeds AI, Inc. | $0.96 | — | — | — | — | $2.94M |
| PRFXPRF Technologies Ltd. | $0.96 | — | 0.1x | — | -90.37% | $2.92M |
| BIAFbioAffinity Technologies, Inc. | $4.87 | — | 0.6x | — | -1860.15% | $2.88M |
| GNPXGenprex, Inc. | $3.67 |
About the company
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
- 2
- Bedminster, United States
Company description provided by Yahoo Finance.